Replies to post #194589 on Biotech Values

[belgiumsui]

SAN DIEGO, Aug. 24, 2015 /PRNewswire/ -- Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) reported today the successful implementation of its gene silencing technology, covered by patent # 8,263,571, in killing cancer stem cells. The technology involves using RNA interference to block expression of the cancer-sustaining gene Brother of the Regulator of Imprinted Sites (BORIS) by a process termed "gene silencing".

In a publication in the peer-reviewed journal PLoS One[1], independent researchers at the Lausanne University Hospital, Switzerland reported that blocking the BORIS gene results in a profound reduction of breast cancer and colon cancer stem cells. In addition, the researchers verified the original findings that BORIS is a "master orchestrator" of the process of tumor formation, growth and metastasis.

"From 2006-2008, together with a team of scientists from the Institute of Molecular Medicine and the National Institutes of Health, we published that vaccinating against BORIS results in immune response against and tumor regression in breast cancer, melanoma, and glioma[2],[3],[4]. Subsequently we published that gene silencing of BORIS can be utilized to selectively kill breast cancer cells[5]," stated Thomas Ichim, Ph.D, Chief Scientific Officer of Regen BioPharma. "As we saw in the recent publication, the role of BORIS as an "Achilles Heel" of cancer is becoming more and more apparent. We are currently in the process of advancing our gene-silencing based approaches, in part by leveraging lessons we are learning during dCellVax development, in order to file an IND for BORIS gene silencing technology."

Regen BioPharma is currently using gene silencing for immune modulation in its dCellVax program, as well as various nuclear receptors in its other cancer stem cell targeting program.

"The current programs in development, HemaXellerate, dCellVax, and gene silencing of nuclear receptors are all intertwined so that experiences from one program help to accelerate the other programs. By collaborating with academic and corporate entities on a continual basis, we strive to be at the cutting edge of science, while rapidly aiming to commercialize and add value to our science," said David Koos, PhD, Chairman and CEO of Regen BioPharma.

ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
[phone] Phone
[phone] Fax
www.regenbiopharma.com
[e-mail]

[biomaven0]

>>Some oncology bios have gotten really cheap

So let me take this as an opportunity to talk about long term biotech investing strategy in general - I'll use TRIL as an example.

You have to think of stock in a company like TRIL as a lottery ticket. If the drug pans out well there will likely be a massive payout. If it does not, likely the stock goes to close to zero. (There are obviously some intermediate possible outcomes, but for a stock like this the extremes dominate). Further, this is not the sort of stock where you will have to go to a Phase III to know if it works - likely Phase IB (after the initial safety studies in lymphoma) will provide a lot of information. So this is not a stock which will have to raise a bunch of money prior to supportive data or a partnership.

So from my perspective, a stock like TRIL should be pretty much disconnected from the rest of the market from a fundamental viewpoint. Really what happens in China or with interest rates or oil prices (or even drug prices) is close to irrelevant to the company.

Now that is not to say the stock of a biotech like this will ever be divorced from the sector - all valuations are comparative, and all development-stage biotechs need to raise capital at regular intervals - thus they all share finance risk as a component of their valuation.

But certainly from my perspective TRIL should be one of the most "isolated" stocks from the rest of the world. So in general it's a good stock to buy when the whole market is down and nobody wants to hear about it, and a good stock to sell when everyone is talking about it. And as for the rest, the clinical results will eventually drive the stock price one way or the other.

Peter